menu
    • menu
    [{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SciClone Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Naxitamab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase IV","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Parexel | National Cheng-Kung University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Parexel | National Cheng-Kung University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Parexel | National Cheng-Kung University Hospital"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"DNA||Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"EpicentRx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Oncology","graph2":"Phase III","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"EpicentRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"RRx-001","moa":"Free radical (FRD)","graph1":"Oncology","graph2":"Phase III","graph3":"SciClone Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"SCV-07","moa":"immunomodulators","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciClone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SciClone Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Tarveda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Sciclone Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"SciClone Pharmaceuticals \/ Sciclone Pharmaceuticals"},{"orgOrder":0,"company":"SciClone Pharmaceuticals","sponsor":"Jia Fan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Thymalfasin","moa":"Immune","graph1":"Oncology","graph2":"Phase IV","graph3":"SciClone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciClone Pharmaceuticals \/ Jia Fan","highestDevelopmentStatusID":"11","companyTruncated":"SciClone Pharmaceuticals \/ Jia Fan"}]

    Find Clinical Drug Pipeline Developments & Deals by SciClone Pharmaceuticals

    Menu

    SciClone Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telavancin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Cumberland Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vibativa Receives Marketing Approval in China

                            Details : Vibativ (telavancin) is a lipoglycopeptide antibacterial indicated for the treatment of adult patients with complicated skin & skin structure infections caused by susceptible Gram-positive bacteria.

                            Product Name : Vibativ

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Telavancin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Cumberland Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Menarini

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Comm...

                            Details : Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory a...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 07, 2023

                            Lead Product(s) : Elacestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Menarini

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naxitamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Mainten...

                            Details : Naxitamab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : Naxitamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Second Affiliated Hospital, Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

                            Details : Thymalfasin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : Thymalfasin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Second Affiliated Hospital, Soochow University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : EpicentRx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Do...

                            Details : RRx-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 04, 2022

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : EpicentRx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Menarini

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Tr...

                            Details : Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue...

                            Product Name : Vaborem

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Meropenem,Vaborbactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Menarini

                            Deal Size : $113.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

                            Details : PT-112 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Biliary Tract Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2022

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Tarveda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for ...

                            Details : Tarveda and SciClone’s licensing agreement will permit SciClone to develop, manufacture and commercialize a preclinical-stage product portfolio of miniature drug conjugates that consist of a PI3K inhibitor payload moiety, a linker and HSP90 binding moi...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Tarveda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : EpicentRx

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EpicentRx and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China

                            Details : Under the terms of the agreement, SciClone will obtain exclusive licensing rights to co-develop and commercialize RRx-001, for the treatment of cancer in humans, within Greater China territory, including mainland China, Hong Kong, Macau and Taiwan.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 01, 2020

                            Lead Product(s) : RRx-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : EpicentRx

                            Deal Size : $120.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SciClone Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellu...

                            Details : PT-112 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2018

                            Lead Product(s) : Imifoplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth